Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
BMC Cancer|May 7, 2013
High CRP values predict poor survival in patients with penile cancerSandra Steffens, Andreas Al Ghazal, Julie Steinestel, et al.
BMC Urology|October 24, 2013
Elevated C-reactive protein values predict nodal metastasis in patients with penile cancerAndreas Al Ghazal, Sandra Steffens, Julie Steinestel, et al.
European Urology|July 16, 2013
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abirateroneAndres Jan Schrader, Martin Boegemann, Carsten-H Ohlmann, et al.
Urologie (Heidelberg, Germany)|October 9, 2025
[Self-critical, multicenter analysis of treatment and coding quality using the example of nephroureterectomy on the basis of billing data]Nici Markus Dreger, Christine Lenhart, Friedrich-Carl von Rundstedt, et al.
Neoplasia (New York, N.Y.)|July 14, 2011
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cellsStephanie M Wittig-Blaich, Lukasz A Kacprzyk, Thorsten Eismann, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2013
Small renal cell carcinomas--how dangerous are they really? Results of a large multicenter studySandra Steffens, Kerstin Junker, Frederik C Roos, et al.
The Journal of Experimental Medicine|March 28, 2012
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33Ninel Azoitei, Christopher M Hoffmann, Jana M Ellegast, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2012
Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre studySandra Steffens, Martin Janssen, Frederik C Roos, et al.
BJU International|September 24, 2013
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)Susanne Krege, Heidrun Rexer, Frank vom Dorp, et al.
Virchows Archiv : an International Journal of Pathology|September 3, 2014
Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor sizeSandra Steffens, Frederik C Roos, Martin Janssen, et al.
Pageof 12